Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE stage II colon cancer ctDNA-guided adjuvant chemotherapy trial
2018-003691-12Phase 3Active
- Sponsor
- Technische Universität Dresden
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in colon cancer (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Disease-free survival. Started Aug 2019; status: active.
02
Drugs
capecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2018-003691-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003691-12.